North America is witnessing significant developments in B-cell non-Hodgkins lymphoma treatment, driven by advancements in cancer diagnostics, immunotherapy, targeted medicines, and personalized healthcare. Healthcare providers across the region are increasingly adopting molecular and biomarker-based approaches to guide treatment decisions and improve patient outcomes. The presence of leading...